Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand
Abstract A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity, was very low (0.1%). This finding is consistent with limited community transmission and provides robust evidence to support New Zealand’ s successful elimination strategy for COVID-19..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 02. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Carlton, Lauren H. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.04.12.21255282 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI020379307 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI020379307 | ||
| 003 | DE-627 | ||
| 005 | 20231205150353.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210421s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.04.12.21255282 |2 doi | |
| 035 | |a (DE-627)XBI020379307 | ||
| 035 | |a (biorXiv)10.1101/2021.04.12.21255282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Carlton, Lauren H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in New Zealand |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity, was very low (0.1%). This finding is consistent with limited community transmission and provides robust evidence to support New Zealand’ s successful elimination strategy for COVID-19. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Chen, Tiffany |4 aut | |
| 700 | 1 | |a Whitcombe, Alana L. |0 (orcid)0000-0002-1951-3469 |4 aut | |
| 700 | 1 | |a McGregor, Reuben |4 aut | |
| 700 | 1 | |a Scheurich, Greg |4 aut | |
| 700 | 1 | |a Sheen, Campbell R. |4 aut | |
| 700 | 1 | |a Dickson, James M. |4 aut | |
| 700 | 1 | |a Bullen, Chris |4 aut | |
| 700 | 1 | |a Chiang, Annie |4 aut | |
| 700 | 1 | |a Exeter, Daniel J. |4 aut | |
| 700 | 1 | |a Paynter, Janine |4 aut | |
| 700 | 1 | |a Baker, Michael G. |4 aut | |
| 700 | 1 | |a Charlewood, Richard |4 aut | |
| 700 | 1 | |a Moreland, Nicole J. |0 (orcid)0000-0001-6548-637X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 02. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u https://doi.org/10.1017/S0950268821001643 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.04.12.21255282 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 02 |c 11 | ||